U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

Shares in D-Wave Quantum popped on Wednesday after the company claimed a scientific breakthrough in the journal Science.

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

On March 7, 2025, the District Court for the District of New Jersey entered a Stipulation and Order of Dismissal Without Prejudice in view of ...

The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...

Ratings for Amgen AMGN were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ...

Analysts were pleasantly surprised by the positive phase III data reported for Kyowa Kirin Co. Ltd./Amgen Inc.’s rocatinlimab, a T-cell rebalancing therapy, in moderate to severe atopic dermatitis.

Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

The site is expected to accelerate Amgen’s digital capabilities through artificial intelligence and data science to further advance its pipeline of medicines, while creating significant opportunities ...

U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, Chief Executive Officer Robert Bradway said at the ...